On November 4, 2026, international breast cancer symposium updates reviewed the practice-changing role of Truqap® (Capivasertib 160 mg and 200 mg film-coated tablets) by AstraZeneca in combination with fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer with PIK3CA, AKT1, or PTEN alterations.

Endocrine therapy resistance driven by aberrant activation of the PI3K/AKT/PTEN oncogenic pathway has historically represented a major clinical barrier. Truqap stands as the first ATP-competitive pan-AKT inhibitor to double progression-free survival in this biomarker-altered population.

Through Critical Kare Pharma, certified genuine packs of Truqap Capivasertib Tablets are accessible directly for oncology centers and named patients globally.

The CAPItello-291 Phase 3 Landmarks

The randomized, double-blind CAPItello-291 trial enrolled 708 patients with HR+/HER2- advanced breast cancer who progressed on or after endocrine therapy (including CDK4/6 inhibitors):

• PFS in AKT Pathway-Altered Tumors: Median progression-free survival was 7.3 months with capivasertib plus fulvestrant versus 3.1 months with placebo plus fulvestrant (hazard ratio 0.50, p < 0.001), representing a 50% reduction in risk of progression or death.
• Overall Population: Median PFS was 7.2 vs 3.6 months in the overall cohort (HR 0.60, p < 0.001), confirming broad clinical activity across both altered and non-altered populations.
• Post-CDK4/6 Benefit: Over 69% of patients had previously received a CDK4/6 inhibitor, demonstrating robust overcoming of cell-cycle inhibitor resistance.

Pan-AKT Mechanism & Intermittent Dosing

Capivasertib is a potent, ATP-competitive inhibitor of all three AKT isoforms (AKT1, AKT2, AKT3). By shutting down AKT kinase activity, it blocks downstream phosphorylation of PRAS40, GSK3β, and FOXO, restoring apoptosis in hormone-refractory cancer cells. An intermittent dosing schedule (400 mg twice daily, 4 days on / 3 days off) preserves therapeutic efficacy while allowing insulin and glucose homeostasis recovery, sharply curbing Grade 3 hyperglycemia.

Administration & Named-Patient Logistics

Supplied in 4-days-on / 3-days-off weekly blister packs alongside fulvestrant 500 mg IM monthly. Critical Kare Pharma ensures rapid temperature-monitored international dispatch with batch certificates of analysis.